Arca
Skip to content

Allergies

Drug research and approvals for allergies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 1,212 studies of allergies are recruiting on ClinicalTrials.gov, and Health Canada has authorized 57 drug trials for it since 2013.

  • Recruiting worldwide: 1,212
  • Trials authorized in Canada: 57
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 1,212 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 57; search them all in Canada trials
Sep 18, 2026A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (lou064) in adult and adolescent…REMIBRUTINIB (LOU064) / ALK 762 PEANUTNovartis Pharmaceuticals CorporationPending
Aug 19, 2026Investigating nasal and ocular immune response to conjunctival allergen exposureALLERGENIC EXTRACTS STANDARDIZED GRASS POLLEN / NEGATIVE SKIN TEST CONTROL…DR. ANNE K. ELLISOngoing
Jun 26, 2026Viaskin peanut patch (dbv712) expanded access clinical trial in peanut-allergic children previously enrolled in a dbv712 clinical studyVIASKIN (DBV712)DBV Technologies S.A.Pending
May 4, 2026A phase 2, open label study to assess ad lib consumption of peanut in peanut allergic infants 6-through 12-months-old with epicutaneous immunotherapy with…DBV712 (VIASKIN PEANUT PATCH)DBV Technologies S.A.Ongoing
Mar 11, 2026An open-label, multi-center protocol for patients who have completed a previous novartis sponsored remibrutinib study and are judged by the investigator to…REMIBRUTINIB (LOU064)Novartis Pharmaceuticals CorporationOngoing
Jun 13, 2025A phase 3, double-blind, placebo-controlled, randomized study to assess the safety of epicutaneous immunotherapy with dbv712 250 ¿g in 1-through 3-year old…VIASKIN PEANUT (DBV712)DBV Technologies S.A.Ongoing
May 28, 2025A phase 1b, open-label, exploratory study evaluating the effects of inhaled epinephrine in individuals experiencing systemic allergic reactions during allergy…EPINEPHRINEKOKUA PHARMA INC.Ongoing
Dec 20, 2024A phase 1, open label, single sequence, pharmacokinetic study of bbp01 (epinephrine) intranasal powder with and without nasal allergen challenge versus…EPINEPHRINE (BBP01)BELHAVEN BIOPHARMA, INC.Closed
Nov 8, 2024A single dose, comparative bioavailability study of epinephrine nasal spray and epinephrine intramuscular injection in allergen-challenged subjects under…EPINEPHRINEHikma PharmaceuticalsClosed
Feb 14, 2024A phase 1b, open-label, exploratory study evaluating the effects of inhaled epinephrine in individuals with known or suspected metabisulfite sensitivity…EPINEPHRINEKOKUA PHARMA INC.Closed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.